ACM
ALLO icon

Aquatic Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Aquatic Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-51,894
Closed -$71.1K – 1333
2025
Q4 		$71.1K Buy
+51,894
New +$68.5K ﹤0.01% 1222
2023
Q1 		– Sell
-53,100
Closed -$334K – 1225
2022
Q4 		$334K Sell
53,100
-26,900
-34% -$249K 0.02% 608
2022
Q3 		$864K Buy
+80,000
New +$1.09M 0.08% 299
2022
Q2 		– Sell
-3,700
Closed -$34K – 1166
2022
Q1 		$34K Buy
+3,700
New +$38.5K 0.05% 364

Other funds holding ALLO

P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aquatic Capital Management's ALLO Position: Q1 2026 in Review

Aquatic Capital Management sold out of Allogene Therapeutics (ALLO) in Q1 2026, closing a stake of 51,894 shares — an estimated $71.1K sold.

Aquatic Capital Management first reported a position in ALLO in Q1 2022 and held it in 4 quarters. The position peaked at $864K in Q3 2022. 209 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Aquatic Capital Management reported no remaining Allogene Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Aquatic Capital Management sold 51,894 Allogene Therapeutics shares in Q1 2026, an estimated $71.1K.
  • Aquatic Capital Management first reported a position in Allogene Therapeutics in Q1 2022 and held it in 4 quarters.
  • Aquatic Capital Management's Allogene Therapeutics position peaked at $864K in Q3 2022.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Aquatic Capital Management's 13F filing for Q1 2026, filed 15 May 2026.